Adding Zytiga and Prednisone to Regimen Is Effective in Treating High-Risk Prostate Cancer, Study Finds

Adding Zytiga and Prednisone to Regimen Is Effective in Treating High-Risk Prostate Cancer, Study Finds
Adding Zytiga (abiraterone acetate) plus prednisone to a regimen of radiotherapy and androgen deprivation therapy is effective in treating patients with high-risk prostate cancer, a Phase 2 clinical trial shows. The combination allows researchers to lower the duration of androgen deprivation therapy (ADT), which is associated with significantly increased toxicity when used long-term. The results were presented in an abstract titled, “Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *